38
Participants
Start Date
March 29, 2023
Primary Completion Date
May 28, 2024
Study Completion Date
May 28, 2024
M5717 330 mg
Participants will receive orally 330 mg granules of M5717 in combination with pyronaridine dispersed in water under fasting condition.
M5717 500 mg
Adolescent participants with weight less than (\<) 45 kilograms (kg) will receive orally 500 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
M5717 660 mg
Adult and adolescent participants with weight more than or equal to (\>=) 45 kg will receive orally 660 mg granules of M5717 in combination with pyronaridine dispersed in water once daily under fasting condition.
Pyronaridine 360 mg
Participants will receive 360 mg of pyronaridine tablets in combination with M5717 under fasting condition.
Pyronaridine 360 mg
Participants with weight \>=24 to \<45 kg will receive 360 mg of tablets in combination with M5717 under fasting condition.
Pyronaridine 540 mg
Participants with weight \>=45 to \<65 kg will receive 540 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Pyronaridine 720 mg
Participants with weight \>=65 kg will receive 720 mg of Pyronaridine tablets in combination with M5717 under fasting condition.
Institut de Recherche en Sciences de la Santé (IRSS), Nanoro
Groupe de Recherche Action en Santé (GRAS), Ouagadougou
Centre de Recherches Médicales de Lambaréné (CERMEL), Lambaréné
Centro de Investigação em saúde de Manhiça/Fundação Manhiça (CISM/FM), Maputo
Infectious Diseases Research Collaboration (IDRC), Tororo
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
INDUSTRY